Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luis Madera Marin

Nephrology Albuquerque, NM Medical Doctor

NPI 1689166795 CMS profile 4631079

Msc10 5550 1 University Of New Mexico, Albuquerque, NM 87131

Open in the dashboard

General payments

$7,155

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Madera Marin of Albuquerque, NM is reported in the CMS Open Payments database as having received $7,155 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $156 4
2024 General $441 4
2023 General $1,107 30
2022 General $2,911 78
2021 General $1,263 38
2020 General $555 19
2019 General $723 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Madera Marin
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Luis Madera Marin were reported at $156. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Luis Madera Marin Nephrology median Middle half National median
2019 $723 $236 $90–$588 $163
2020 $555 $135 $46–$364 $114
2021 $1,263 $202 $67–$551 $132
2022 $2,911 $242 $77–$695 $149
2023 $1,107 $254 $84–$766 $160
2024 $441 $300 $99–$852 $164
2025 $156 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $939 22 payments
  2. Amgen Inc. $760 9 payments
  3. AstraZeneca Pharmaceuticals LP $724 19 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $605 18 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $601 8 payments
  6. Janssen Pharmaceuticals, Inc $541 15 payments
  7. Dexcom, Inc. $299 11 payments
  8. Novo Nordisk Inc $295 14 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $248 10 payments
  10. PBG Puerto Rico LLC $234 11 payments
  11. Other $1,908 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,126 188 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $637 7 payments
  2. Kerendia $626 10 payments
  3. JARDIANCE $605 18 payments
  4. SOLIQUA 100/33 $569 13 payments
  5. FARXIGA $491 11 payments
  6. TOUJEO $467 6 payments
  7. XARELTO $381 10 payments
  8. Ozempic $295 14 payments
  9. RYBELSUS $270 13 payments
  10. LifeVest $248 10 payments
  11. Other $4,120 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record